Previous 10 | Next 10 |
Gainers: ChemoCentryx (NASDAQ: CCXI ) +261% . More news on: ChemoCentryx, Inc., Akerna Corp., Proteostasis Therapeutics, Inc., Stocks on the move, Read more ...
ChemoCentryx (NASDAQ: CCXI ) +323% on positive test results . More news on: ChemoCentryx, Inc., Nutanix, Inc., InflaRx N.V., Stocks on the move, Read more ...
Gainers: CCXI +305.7% . IFRX +24.1% . NTNX +19.2% . AMBA +6.6% . ETRN +3.8% . More news on: ChemoCentryx, Inc., InflaRx N.V., Nutanix, Inc., Stocks on the move, Read more ...
Publication of positive results is almost always a highly positive trigger for a pharmaceutical or biotech stock, and that is what IFRX stock experienced this morning. In a new development today, InflaRx NV (NASDAQ:IFRX) announced highly positive results from its Phase B clinical trial, c...
Livongo Health (NASDAQ: LVGO ) +22% after Q3 results . More news on: Livongo Health, Inc., DexCom, Inc., InflaRx N.V., Stocks on the move, Read more ...
Nano cap InflaRx N.V. (NASDAQ: IFRX ) is up 16% premarket on robust volume in reaction to positive results from an open-label extension from a Phase 2b clinical trial, SHINE , evaluating lead candidate IFX-1 in patients with an inflammatory skin condition called hidradenitis s...
InflaRx (NASDAQ: IFRX ): Q3 GAAP EPS of -€0.56 beats by €0.01 . Cash and cash equivalents of €27M Shares +32% Press Release More news on: InflaRx N.V., Earnings news and commentary, Healthcare stocks news, ,
Recently announced results of open label extension part of SHINE Phase IIb study confirm potential of IFX-1 in Hidradenitis Suppurativa and warrant evaluation of future development Company announces updated strategy with focus on selected indications for its anti-C5a complement technol...
70.6% of week 16 HiSCR responders maintain response throughout week 40 while 41.8% of non-responders become responders (total HiSCR rate = 56.3% at end of treatment) 78.2% of OLE patients complete extension period and show marked reduction in all inflammatory lesions IFX-1 long-te...
Gainers: CNFR +22.2% . VNDA +19.9% . IFRX +18.1% . DXCM +17.5% . IVC +15.6% . More news on: Conifer Holdings, Inc., Vanda Pharmaceuticals Inc., InflaRx N.V., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development ...
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential differentiation and medical role of INF904 in initially targeted indications and inflammation & imm...
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held f...